

# 组蛋白去乙酰化酶抑制剂治疗乳腺癌的临床研究

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R] 期数: 2019年18期 页码: 3338-3341 栏目: 综述 出版日期: 2019-08-08

**Title:** Progress of histone deacetylase inhibitors in breast cancer treatment

**作者:** 黄美玲; 肖晶晶; 延常姣; 凌瑞

空军军医大学西京医院甲乳血管外科,陕西 西安 710032

**Author(s):** Huang Meiling; Xiao Jingjing; Yan Changjiao; Ling Rui

Department of Thyroid,Breast and Vascular Surgery,Xijing Hospital,Air Force Medical University,Shaanxi Xi'an 710032,China.

**关键词:** 组蛋白去乙酰化酶抑制剂; 乳腺癌; 临床研究

**Keywords:** HDACIs; breast cancer; clinical trials

**分类号:** R737.9

**DOI:** 10.3969/j.issn.1672-4992.2019.18.042

**文献标识码:** A

**摘要:** 组蛋白去乙酰化酶抑制剂 (histone deacetylase inhibitors, HDACIs) 作为第一个成功用于癌症治疗的表观遗传学相关药物,能够有效解除对抑癌基因转录的阻滞,已成为极具潜力的抗癌药物。近年来,HDACIs在乳腺癌治疗领域中的临床研究逐渐开展,已有个别HDACIs在大型临床研究中表现出较强的抗癌活性。本文针对HDACIs在乳腺癌治疗领域开展的临床研究作一综述,有利于临床医师更好的了解HDACIs在乳腺癌治疗中的现状与进展。

**Abstract:** As the first epigenetic drug successfully applied for cancer treatment,histone deacetylase inhibitors (HDACIs) can relieve the inhibition to suppressor genes and has developed as a potential anticancer drug.Recently,HDACIs have been used to for breast cancer treatment.Several clinical trials have proved the strong anticancer efficacy of HDACIs.Here we reviewed the clinical studies proceeded in breast cancer therapy using HDACIs,which would be of great significance for clinicians to know the current status and progress of HDACIs in breast cancer treatment.

## 参考文献/REFERENCES

- [1] Siegel RL,Miller KD,Jemal A.Cancer statistics,2019 [J] .CA:A Cancer Journal for Clinicians,2019,69(1):7-34.
- [2] Lakshmaiah KC,Jacob LA,Aparna S,et al.Epigenetic therapy of cancer with histone deacetylase inhibitors [J] .Journal of Cancer Research and Therapeutics,2014,10(3):469-478.
- [3] de Ruijter AJ,van Gennip AH,Caron HN,et al.Histone deacetylases (HDACs):characterization of the classical HDAC family [J] .The Biochemical Journal,2003,370(Pt 3):737-749.
- [4] Weichert W.HDAC expression and clinical prognosis in human malignancies [J] .Cancer Letters,2009,280(2):168-176.
- [5] Ropero S,Esteller M.The role of histone deacetylases (HDACs) in human cancer [J] .Molecular Oncology,2007,1(1):19-25.
- [6] Eckschlager T,Plch J,Stiborova M,et al.Histone deacetylase inhibitors as anticancer drugs [J] .International Journal of Molecular Sciences,2017,18(7):1414-1439.
- [7] Hull EE,Montgomery MR,Leyva KJ.HDAC inhibitors as epigenetic regulators of the immune system:Impacts on cancer therapy and inflammatory diseases [J] .BioMed Research International,2016(2016):8797206.
- [8] LI XH,HUANG ML,LIU LN,et al.Cyclopeptide histone deacetylase inhibitors [J] .Progress in Chemistry,2014,26(09):1527-1536. [李晓晖,黄美玲,刘丽娜,等.环肽类组蛋白去乙酰化酶抑制剂 [J] .化学进展,2014,26(09):1527-1536.]
- [9] Damaskos C,Garmpis N,Valsami S,et al.Histone deacetylase inhibitors:An attractive therapeutic strategy against breast cancer [J] .Anticancer Research,2017,37(1):35-46.
- [10] HUAN D,YU XQ,LI J.Advances in pharmacological and toxicological studies on the antitumor drug vorinostat [J] .Journal of Huaihai Medicine,2014,32(04):415-416. [宦娣,余兴群,李杰.抗肿瘤药伏立诺他药理毒理研究进展 [J] .淮海医药,2014,32(04):415-416.]
- [11] Duvic M,Talpur R,Ni X,et al.Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid,SAHA) for refractory cutaneous T-cell lymphoma (CTCL) [J] .Blood,2007,109(1):31-39.
- [12] ZHENG YD,YANG PC,ZHAO X.New progress of the clinical application of vorinostat [J] .Chinese Journal

of New Drugs,2015,24(08):900-903. [郑亚东,杨平传,赵雪.伏立诺他临床应用新进展 [J].中国新药杂志,2015,24(08):900-903.]

[13] Ramaswamy B,Fiskus W,Cohen B,et al.Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer:evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo [J].Breast Cancer Research and Treatment,2012,132(3):1063-1072.

[14] Tu Y,Hershman DL,Bhalla K,et al.A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer [J].Breast Cancer Research and Treatment,2014,146(1):145-152.

[15] Munster PN,Thurn KT,Thomas S,et al.A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer [J].British Journal of Cancer,2011,104(12):1828-1835.

[16] WANG XY,CHENG MS.Panobinostat [J].Chinese Journal of Medicinal Chemistry,2015,25(05):412. [王晓宇,程卯生.帕比司他 [J].中国药物化学杂志,2015,25(05):412.]

[17] XU QM.Application progress of anticancer drug panobinostat [J].Modern Instruments & Medical Treatment,2017,23(04):90-92. [徐奇谋.抗癌药帕比司他临床应用进展 [J].现代仪器与医疗,2017,23(04):90-92.]

[18] Tan WW,Allred JB,Moreno-Aspitia A,et al.Phase I study of panobinostat (LBH589) and letrozole in postmenopausal metastatic breast cancer patients [J].Clinical Breast Cancer,2016,16(2):82-86.

[19] Bouchain G,Delorme D.Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors:synthesis and antiproliferative evaluation [J].Current Medicinal Chemistry,2003,10(22):2359-2372.

[20] LI PK,XIAO GZ,TIAN H,et al.A histone deacetylase inhibitor:entinostat [J].Drugs & Clinic,2015,30(03):341-344. [李鹏坤,肖桂芝,田红,等.组蛋白去乙酰化酶抑制剂恩替诺特 [J].现代药物与临床,2015,30(03):341-344.]

[21] Yardley DA,Ismail-Khan RR,Melichar B,et al.Randomized phase II,double-blind,placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor [J].J Clin Oncol,2013,31(17):2128-2135.

[22] Connolly RM,Rudek MA,Piekarz R.Entinostat:a promising treatment option for patients with advanced breast cancer [J].Future Oncology (London,England),2017,13(13):1137-1148.

[23] Tomita Y,Lee MJ,Lee S,et al.The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer:Correlative analysis of ENCORE 301,a randomized,placebo-controlled phase II trial of exemestane with or without entinostat [J].Oncoimmunology,2016,5(11):e1219008.

[24] SHI YX.China's first class drug for the treatment of peripheral T-cell lymphoma cidabentamine on the market [J].Capital Food and Medicine,2015,22(09):66. [食药讯.我国首批治疗外周T细胞淋巴瘤一类新药西达本胺片上市 [J].首都食品与医药,2015,22(09):66.]

[25] ZHOU Y,WANG YN,ZHANG K,et al.Chidamide reverses endocrine resistance in estrogen receptor-positive breast cancer [J].Journal of Shenzhen University Science and Engineering,2018,35(04):339-344. [周游,王雅楠,张堃,等.ER阳性乳腺癌中西达本胺逆转内分泌耐药 [J].深圳大学学报(理工版),2018,35(04):339-344.]

[26] Chidamide was approved by TFDA for III stage clinical trial [J].Chinese Journal of Clinical Rational Drug Use,2017,10(11):12. [西达本胺获台湾TFDA核准进入乳腺癌III期临床试验 [J].临床合理用药杂志,2017,10(11):12.]

---

**备注/Memo:** National Natural Science Foundation of China(No.81572917);国家自然科学基金面上项目 (编号: 81572917) ;空军军医大学第一附属医院学科助推项目 (编号: XJZT18MJ30)

---

更新日期/Last Update: 1900-01-01